NICMP

(redirected from Non-Ischemic Cardiomyopathy)
AcronymDefinition
NICMPNon-Ischemic Cardiomyopathy
NICMPNavy Interoperability Configuration Management Plan
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
The final diagnosis was non-ischemic cardiomyopathy, putting him at high risk for cardiac arrest.
(11.) Kadish A, Dyer A, Daubert JP, et al for the Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators.
Although both reparative and reactive fibrosis occurs in the non-ischemic cardiomyopathy, reactive fibrosis usually predominate the deranged myocardial histology (8).
In this review we will portray advantages of cardiac magnetic resonance imaging for detecting cardiac fibrosis and its importance in clinical practice, moreover we will discuss how CMR based approach may provide insights for prognostic determinants of non-ischemic cardiomyopathy such as LV remodeling, diastolic dysfunction, brain natriuretic peptide levels.
The Arizona state legislature's decision to eliminate Medicaid funding for lung, pancreas only, pancreas after kidney, heart for non-ischemic cardiomyopathy, and liver for diagnosis of hepatitis C went into effect on October 1, 2010.
A heart biopsy revealed an unusual amount of scar tissue for a patient with such a short history of non-ischemic cardiomyopathy, suggesting limited potential for recovery.
PHILADELPHIA, Pa., November 20, 2014 -- The first first patient in the University of Pennsylvania's Phase 2a clinical trial for chronic heart failure (HF) of non-ischemic cardiomyopathy has been dosed.
The trial will use hypoxically grown stem cells to address non-ischemic cardiomyopathy, a complex condition in which patients have living cardiomyocytes that are not contracting as they should.
subsidiary, is launching a Phase 2a clinical trial for chronic heart failure (HF) patients with non-ischemic cardiomyopathy.
He and his group are participating in Phase IIII clinical trials of bone marrow-derived and peripheral blood-derived stem cells for the treatment of patients with ischemic and non-ischemic cardiomyopathy, advanced coronary artery disease, and recent myocardial infarction (3-21 days).
Full browser ?